Infants aged 3-24 months with fever without source in the emergency room: Characteristics, management and outcome;Lactante de 3-24 meses con fiebre sin foco en urgencias: Características, tratamiento y evolución posterior

Anales de Pediatria

Volumn 62, Issue 6, 2005, Pages 522-528

  Mintegi Raso, S ^a   Gonzalez Balenciaga M ^a   Perez Fernandez A ^a   Pijoan Zubizarreta J I ^a   Capape Zache S ^a   Benito Fernandez J ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Bacteremia; Emergency; Fever; Infant

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE;

ARTICLE; BACTERIAL MENINGITIS; BLOOD CELL COUNT; BLOOD CULTURE; CHILD; EMERGENCY WARD; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; URINARY TRACT INFECTION;

EID: 21344461934     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075544     Document Type: Article

References (24)

1. Mintegi S, Benito J, García S, Corrales A, Bartolomé MJ, Trebolazabala N. Demanda y asistencia en un servicio de urgencias hospitalario. An Pediatr (Barc). 2004;61:156-61.
2. Shapiro ED, Aaron NH, Wald ER, Chiponis D. Risk factors for development of bacterial meningitis among children with occult bacteremia. J Pediatr. 1986;109:15-9.
3. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-9.
4. Poehling KA, Lafleur BJ, Szilagyi PG, Edwards KM, Mitchel E, Barth R, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. 2004;114:755-61.
5. Grupo de Trabajo sobre el Niño Febril. Sociedad Española de Urgencias de Pediatría. El niño febril. Resultados de un estudio multicéntrico. An Esp Pediatr. 2001;55:5-10.
6. Baraff LJ, Bass JW, Fleisher GR, Klein JO, McCracken GH Jr, Powell KR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med. 1993;22:1198-210.
7. Klein JO, Pelton SI, Barnett E, Culpepper L, Shinefield H. Management of pediatric pneumococcal diseases in the era of the pneumococcal conjugate vaccine. Disponible en: http://www. medscape.com/viewprogram/2824_pnt [visitado el 07-09-04].
8. Baraff LJ. Clinical policy for children younger than three years presenting to the emergency department with fever [editorial]. Ann Emerg Med. 2003;42:546-9.
9. Belfer RA, Gittelman MA, Muniz AE. Management of febrile infants and children by pediatric emergency medicine and emergency medicine: Comparison with practice guidelines. Pediatr Emerg Care. 2001;17:83-7.
10. Isaacman DJ, Kaminer K, Veligeti H, Jones M, Davis P, Mason JD. Comparative practice patterns of emergency medicine physicians and pediatric emergency medicine physicians managing fever in young children. Pediatrics. 2001;108:354-8.
11. Luszczak M. Evaluation and management of infants and young children with fever. Am Fam Physician. 2001;64:1219-26.
12. Grupo de Trabajo de Codificación Diagnóstica de la Sociedad de Urgencias de la Asociación Española de Pediatría. Codificación diagnóstica en urgencias de pediatría. An Esp Pediatr. 2000;53:261-72.
13. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000;106:367-76.
14. Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med. 1998;152:624-8.
15. American College of Emergency Physicians Clinical Policies Committee; American College of Emergency Physicians Clinical Policies Subcommittee on Pediatric Fever. Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med. 2003;42:530-45.
16. Bachur R, Perry H, Harper MB. Occult pneumonias: Empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med. 1999;33:166-73.
17. Baraff LJ. Empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med. 1999;33:480.
18. Green SM, Rothrock SG. Evaluation styles for well-appearing febrile children: Are you a "risk-minimizer" or a "test-minimizer"? Ann Emerg Med. 1999;33:211-4.
19. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am. 1999;46:1073-109.
20. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
21. Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason EO Jr. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatrie center 2 years after licensure of the pneumococcal conjugate vaccine. Pediatrics. 2003;111:896-9.
22. Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000;36:602-14.
23. Nigrovic LE, Malley R. Evaluation of the febrile child 3 to 36 months old in the era of pneumococcal conjugate vaccine: Focus on occult bacteremia. Clin Ped Emerg Med. 5:13-9.
24. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of conjugate pneumococcal vaccine: A cost-effectiveness analysis. Pediatrics. 2001;108:835-44.